contributed equally to this work; S.K. Mishra and J-H. Kang contributed equally to this work Chaga mushroom (Inonotus obliquus) has been used as a folk remedy for several illnesses including gastrointestinal disorders. We recently reported the potent anti-inflammatory effect of chaga extract in experimental colitis. However, its effects on colorectal cancer (CRC) have not been clearly elucidated. We investigated the effects of an aqueous extract of Inonotus obliquus (IOAE) in vitro in HCT116 and DLDl cell lines and in vivo for adenoma in APOlfi"l+ mice and colitis-associated colon cancer in AOM/DSS-treated mice. Results show that IOAE suppressed the proliferation of both cell lines, and inhibited the growth of intestinal polyps in APClfi"l+ and colon tumors in AOM/DSS-treated mice. IOAE induced mitochondrial intrinsic pathway of apoptosis, autophagy, and S phase cell cycle arrest. IOAE suppressed the expression levels of iNOS and Cox-2 and mRNA levels of pro-inflammatory cytokines (IL-6, IL-l(l, TNF-(l and IFN-y) in the intestine of mice models. IOAE suppressed the nuclear levels of (l-catenin and inhibited its downstream targets (cyclin Dl and c-Myc) along with CRC oncogene CDK8. IOAE inhibited the expression of NF-KB at cytoplasmic and nuclear levels. Our results demonstrate that IOAE possess potent anti-inflammatory and anti-proliferative properties through downregulation of Wnt/(l-catenin and NF-KB pathways. Considering recent anticancer approaches involving natural products with minimal side effects, we advocate that Inonotus obliquus could be a beneficial supplement in prevention of colorectal cancer.
ulcerative colitis and Crohn's disease, lead to colitis-associated colorectal cancer (CACC), a difficult-to-treat subtype of colorecta1 carcinoma with high mortality (I, 2). Most co1orectal tumors arise sporadically and only 5-10% cases constitute a heritable familial adenomatous polyposis (FAP) condition (I, 2). Some of the essential stages of cancer development such as formation of aberrant crypt foci, polyps, adenomas and carcinomas, are similar between non-inflammatory CRC and CACC (2) .
Chronic inflammation involves several molecular events in multistep colorectal carcinogenesis such as intestinal immune system dysfunction, overproduction of cytokines and reactive-oxygen species (ROS) and nitrogen species (2) . Chronic inflammation has been found associated with the development of CACC featuring overproduction of pro-inflammatory cytokines such as interleukin (IL)-6, IL-I p, IL-17 and tumor necrosis factoralpha (TNF-a) (2) . Molecular mechanisms in inflammation-driven carcinogenic developments are still under exploration in the process of developing new therapeutic strategies. The nuclear factor-kappa b (NF-KB) pathway plays a key role in regulating the immune response and inflammation in pathologic condition processes (2) . NF-KB pathway governs multiple mechanisms in colorectal carcinogenesis and tumor survival through inhibition ofapoptotic cellular pathways, induction of proliferation, and controlling the expression of genes involved in immune and inflammatory function (3) . The proliferation ofCRC cells towards tumorigenic development is recurrently associated with mutations in cancer related genes and epigenetic silencing of tumor suppressor genes (4) . The human adenomatous polyposis coli (APC) is a tumor-suppressor gene, directly associated to the development of both hereditary and sporadic forms of CRC (4) . APC gene controls the cytoplasmic levels of p-catenin. Mutations in APC cause aberrant activation of p-catenin leading to transcriptional over-activation of several target genes of the Wnt/pcatenin pathway such as cyclin DI and c-Myc (4, 5) . Aberrant activation of the canonical Wnt signaling components occurs in most CRC cases contributing to their growth, invasion, and survival (5) . The induction of Wnt/p-catenin activity has shown direct relationship with the degree of apoptosis in several human colon cancer cell lines (6) . Therefore, targeting NF-KB inflammation pathways together with Wnt/p-catenin signaling may act to control colorectal carcinogenesis.
Environmental and dietary factors have been considered as major risk factors in the development ofCRC (7, 8) . Recently, an upsurge in identification of natural products in CRC chemoprevention has been hailed by many investigators (7) . The edible medicinal mushroom Inonotus obliquus, commonly known as Chaga, has been used as a folk remedy in Russia and Eastern Europe since the sixteenth century for a wide variety of human diseases (9) . Chaga tinctures alone or in combination with other herbs have been used as remedies for the prophylaxis and treatment of various gastric disorders including duodenal ulcers and gastritis (9) . Inonotus obliquus have shown inhibitory effects of colon cancer cell proliferation (10) , free radical scavenging activity counteracting oxidative DNA damage (II), and inhibited the expression of inflammatory mediators in murine macrophage cell line (12) . Recently, we reported potent anti-inflammatory activity of Inonotus obliquus in DSS-induced colitis in mice. We found that Inonotus obliquus down-regulates the expression of inflammatory mediators such as TNF-a, inducible nitric oxide synthase (iNOS), IL-6 and IL-I p (13) . Suppression of colonic inflammation by Inonotus obliquus showed a possibility that it might act help in suppression of CRC development.
In this study, we investigated the effect of an aqueous extract of Inonotus obliquus (IOAE) against the human CRC cell lines HCTll6 and DLD I and mice models of colorectal adenoma (APCMin/+) and CACC (AOM/DSS-treated). We investigated the anti-inflammatory and anti-proliferative mechanisms of IOAE associated with the anticancer activities against intestinal tumorigenesis.
MATERIALS AND METHODS

Preparation ofaqueous extracts from Inonotus obliquus
Chaga extract was purchased from K&T Limited Company (Biysk, Russia) through The Korea Ginseng Co. Ltd. (Seoul, Korea). The aqueous extract from Inonotus obliquus (IOAE) was prepared as described earlier (13) by extracting powdered fruiting bodies (10 gm) in 200 ml of warm water (40°C). Quantitative preparations of IDAE for experimental application were freshly prepared by dissolving IOAE in autoclaved triple distilled water. Chemical composition ofIOAE was analyzed as described previously (15) .
Cell cultures!
Human colorectal cancer cell lines (HCTlI6, DLD I, HT29, SW620 and CoL0205) were purchased from American Type Culture Collection (ATCC) and maintained in RPMI 1640 medium (Gibco Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Hyclone, UT), 2 mM L -glutamine, 100 units/ml penicillin and 100 ug/ml streptomycin (Gibco Invitrogen) at 37°C in humidified atmosphere of 5% CO 2 ,
Cell viability assay
Cells were plated at 4,000 cells/well density in 96-well plates and treated with the indicated concentrations of IOAE for 48 h. Cell viability assay was performed using 10 ml of 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2Htetrazolium bromide (MTT) (5 mg/ml) as described earlier (14) . MTT reduction was quantified by reading absorbance at 570 nm in a microplate reader (Epoch Micro-Volume Spectrophotometer System, USA).
Flow cytometry analysis ofapoptosis
HCTll6 and DLDI cells (2xI0 6) were treated with IOAE (0.2 and 0.5 mg/ml) for 48 h. Apoptosis pattern in cells was assessed by flow cytometry using Annexin V-FITC Apoptosis Detection Kit II (BD Bioscience, San Jose, CA, USA) according to the manufacturer's instructions. Briefly, cells were washed with cold PBS and resuspended in binding buffer (10 mM Hepes/NaOH pH 7.4, 140 mM NaCl, 2.5 mM CaCI 2 ) , then stained with FITC-conjugated annexin V and subjected to flow cytometry analysis using FACSCalibur (BD Bioscience, San Jose, CA, USA).
Cell cycle analysis
HCT 116 and DLD I cells (2x I06/ ml) cells were treated with IOAE (0.2 and 0.5 mg/ml) for 48 h. Cells were harvested and total Ixl0 6 cell (counted with trypan blue) were centrifuged to pellet and fixed in 70% ethanol for I h at 4°C. Resuspended the cells in I ml of Krishan's buffer containing 50 ug/ml propidium iodide (PI) for I h at 4°C and washed with phosphate buffered saline (PBS). Cells were then analyzed by flow cytometry using FACSCalibur (BD Bioscience, San Jose, CA. USA) and the percentage of cells in G lIGO, S, and G2/M phases were determined by the Modfit LT program (Verity Software House; ME, USA).
Western blot analysis
HCTll6 and DLDl cells (1xI0 6) were treated with IOAE (0.2 and 0.5 mg/ml) for 48 h. Preparation of wholecell lysates, protein quantification, gel electrophoresis and Western blotting were performed as previously described (14) . For nuclear protein isolation, cells were homogenized with lysis buffer (10 mM Tris HCl pH 7.5 with 2 mM MgCI 2 , 3 mM CaCI 2 , 0.5 M sucrose and Ix protease and phosphatase inhibitor cocktails) and then mixed with Igepal CA-360 solution (0.6%). Cell lysate was centrifuged and supernatant containing cytoplasmic fraction was collected. Pellet was treated with extraction buffer (20 mM HEPES buffer pH 7.9 with 1.5 mM MgCI 2 , 0.42 M NaCl, 0.2 mM EDTA, 25% (v/v) glycerol, 0.1 M DTT, and Ix protease and phosphatase inhibitor cocktails) and then centrifuged to obtain supernatant containing nuclear fraction. APCMinl+mice small intestine (50 mg) was used for protein extraction. Equivalent amounts of protein were separated by SDS-PAGE and immunoblotted with primary antibodies. Protein bands were detected using ECL western blotting detection reagents (AbFrontier, Seoul, Korea).
Mice models AII animal experimental procedures were approved by The Center of Animal Care and Use (CACU) of Gachon University.
APClJinl+ Mice Model: C57BLl6J-Apc M in/J (APCMinl+) mice were obtained from The Jackson Laboratory. Genotyping of APCMinl+ mice was performed using the following primers recommended by The Jackson Laboratory protocol: wild-type forward primer 5' -GCCATCCCTTCACGTTAG-3', Min forward primer 5' -TTCTGAGAAAGACAGAAGTTA-3', and a common reverse primer 5'-TTCCACTTTGGCATAAGGC-3'. Female 5-week-old APCMinl+ mice (n=15) were randomly divided into three treatment groups. Female 5-week-old C57BLl6 mice (n=15) were grouped as non-APCMil/l+ control. Mice were administered with either vehicle control (VH, water) or IOAE (100 or 300 mg/kg) twice a day by oral gavage. The body weights of the mice was recorded every week. Mice were euthanized by CO 2 inhalation and whole intestine was excised and fixed in 10% neutral buffered formalin (BBC Biochemical, Mount Vernon, WA, USA). Intestines from 10 mice in each group were prepared as 'Swiss roll' for full-length histopathology work.
AOMlDSS Mice Model: Female 5-week-old C57BLl6 mice were purchased from Charles River Laboratories (Wilmington, MA, USA). Animals were randomly divided into four groups (n=15). Mice were administered with or without AOMIDSS and either VH or IOAE (100 or 300 mg/kg) twice a day by oral gavage. Colon cancer in mice was induced by single dose intraperitoneal (i.p.) injection ofAOM (10 mg/kg) (Sigma Chemical Co.). One week later, colonic inflammation in mice was induced by 2% (w/v) DSS (MW; 36,000-50,000, MP Biomedical, Solon, OH) in their drinking water for 7 days. Mice in two control groups received normal drinking water and then were administered with either vehicle control (water) or IOAE (300 mg/kg) for 14 weeks. The body weight of mice was recorded every week. In vivo BrdU incorporation assay was used for proliferation assay. Briefly, 0.2 ml of 5-bromo-2'-deoxyuridine (BrdU, 5 mg/ml) solution (Sigma, MO, USA) was i.p. injected in five mice in each group, 2 h before anesthesia. Mice were euthanized by CO 2 inhalation and colons were excised. Colon length was measured from the colocaecal junction to the anal verge and processed for histopathological procedures as described above.
Immunohistochemical staining
The immunohistochemical (IHC) staining of paraffinimbedded intestine sections was performed as described previously (13) . Tissue sections were reacted with appropriately diluted primary antibodies for Cyclin D1, c-Myc, iNOS and Cox-2, and incubated with biotinylated goat anti-rabbit secondary antibody and avidin-biotin peroxidase. Sections were visualized by chromogen 3,3'-diaminobenzidine (Dako, K3466) and counterstained with hematoxylin. The intensity and localization of immunoreactivity against antibodies was viewed under the light microscope (200 x) and evaluated on a scale as described previously (13) . For BrdU labeling, intracellular staining of colon sections was carried out with anti-BrdU antibody conjugate and stained cells were counted under light microscope (200 x).
Reverse transcription-polymerase chain reaction (RT-
res)
Total RNA was extracted from tissue specimens (50-60 mg) in I ml TRlzol Reagent (Invitrogen) according to the manufacturer's instructions. RNA was further purified using the RNeasy Mini kit (Qiagen, CA, USA) and 2 mg RNA was reverse transcribed for cDNA synthesis as described earlier (13) . PCR was performed using cDNA template and gene-specific oligonucleotide primers designed from mouse (Bioneer Corp., South Korea) for IL-6, IL-lP, TNF-a, IFN-y, iNOS and p-actin. Ethidium bromide stained PCR products (10 mL) were visualized on 1.5% agarose gel and densitometric analysis of bands was performed using QuantityOne software (Biorad Laboratories).
Statistical analyses
All values are expressed as means with either standard deviations (SD) or standard error ofmean (SEM), specified at respective experiments. SigmaPlot 10.0 (Systat Inc.) graphing software was used for data analysis and creation of graphs. Statistical significance was calculated by Student's t-test and P values <0.05 were considered statistically significant.
RESULTS
IOAE suppresses proliferation of human colorectal cancer cells by inducing apoptosis and cell cycle arrest
We investigated the effect of IOAE on proliferation of five human CRC cell lines by MTT assay (data not presented). IOAE suppressed the proliferation of cells in a dose-dependent manner. HCTl16 and DLDl cells were screened for further study. IOAE at 0.2 and 0.5 mg/ml inhibited 48 and 62% proliferation ofHCTl16 cells and 40 and 60% proliferation ofDLDl cells ( Fig. lA) . To determine the mechanisms behind growth inhibitory effects of IOAE, we assessed apoptosis induction by FACS. IOAE treatment caused dose-dependent increase in annexin V positive cells (regarded as early apoptotic cells) ( Fig. lB) . As compared to vehicle control, IOAE at 0.2 and 0.5 mg/ml caused early apoptotic transition ofHCTll6 cells by 7.5 and 20.3% and of DLD 1 cells by 8.6 and 20.1 %, respectively ( Fig. 1B) . We also analyzed the effect of IOAE on cell cycle progression by PI staining ofIOAE-treated HCT116 and DLD I (Fig. 1C ). Although cell cycle arrest was clearly observed in HCTl16 cells but DLD 1 cells showed accumulation of cells in S phase. In DLDI cell line, live cells were dose-dependently reduced in G 1 phase by IOAE treatment: 39% (vehicle control), 36.6% (0.2 mg), and 30.5% (0.5 mg). Consequently, live cells were dose-dependently accumulated in S phase: 41% (vehicle control), 46.5% (0.2 mg), and 59% (0.5 mg). Thus, the percentage of cells in G2/M phase was proportionately reduced. Taken together, these results demonstrate anti-proliferative effects of IOAE in HCTl16 and DLDI cell lines by inducing apoptosis.
IOAE activates caspase-9-dependent apoptosis and autophagy
Cancers cells are characterized by high proliferation and slow apoptotic potential, thus reactivating apoptosis is a major artifact in anticancer drug development. Using this approach, we investigated the effect of IOAE on expression 
.'
.' of proteins in caspase cascade. As shown in Fig.  2A , IOAE activated caspase-9 in both cells, as observed by reduced levels of pro-capsase-9 and increased accumulation of cleaved caspase-9, in a dose-dependent manner. IOAE subsequently activated caspase-3 and cleaved its nuclear substrate Poly (ADP-ribose) polymerase (pARP) ( Fig. 2A ). Pro-caspase-8 was also partly activated by IOAE especially in HCTl16 cells ( Fig. 2A) which may be the result of connection between intrinsic and extrinsic pathways of caspase activation (15) . These results clearly demonstrate the activation of caspase-9 dependent mitochondrial intrinsic pathway of apoptosis in IOAE-treated cells. In order to analyze other modes ofcell death, we observed the expression of autophagy related proteins. Autophagy NF-KBI (pI05/p50), and NF-KB2 (pIOO/p52). Thus, we analyzed the effect of IOAE on expression of NF-KB (p65) protein in cytoplasmic and nuclear fractions. IOAE inhibited both the cytoplasmic and nuclear levels of p65 protein in HCT116 and DLD I cells (Fig. 3A) . IOAE mediated inhibition ofNF-KB also validates the inhibition ofanti-apoptotic proteins Bcl-X L and Bcl-2 ( Fig. 3B ) and correlates with the suppression of cell proliferation. IOAE was also found to suppress the levels of a key inflammatory mediator, cyclooxygenase-2 (Cox-2) in both cell lines ( Fig. 3B ). Cox-2 is a transcriptional target of NF-KB signaling pathway which exaggerates inflammation in crosstalk with iNOS. Collectively, these results confirm that IOAE inhibits~-catenin signaling and NF-KB inflammatory pathway leading to growth inhibition of CRC cells.
IOAE suppresses polyp development in APCMinl+ mice
The in vivo anti-tumor effects of IOAE were observed in APCMinl+ mouse, which is considered as the standard experimental model mimicking human intestinal carcinogenesis (17) . These mice carry a germ line nonsense mutation in the APC gene and spontaneously develop multiple polyps in the small and large intestines within a few months (17) . Administration of IOAE showed a tendency to suppress polyps in the intestine of APCMinl+ mice with significant reduction in total polyp count in whole intestine at 300 mg/kg IOAE (P=O.021) ( Fig. 4) . Analysis of the effect of IOAE on different sizes of polyps showed that IOAE more effectively suppressed the count of larger polyps as compared to smaller polyps. Total count of large polyps in whole intestine was significantly reduced by IOAE treatment in a dose-dependent manner (100 mg/kg, P=0.050; 300 mg/kg, P=0.003) (Fig. 4) . Analysis of the regional distribution of polyps in the intestine of APCMinl+ mice showed higher occurrence of polyps in the small intestine (60.63±5.l6) as compared to the large intestine (7.38±1.61) (data not presented). IOAE suppressed total polyp count both in small and large intestines but statistically not significant (P>O.05). The distribution of small and large polyps in intestine showed more interesting results. IOAE significantly reduced the count of large polyps in small intestine in a dose-dependent manner (100 mg/kg, P=0.034; 300 mg/kg, P=0.002). But IOAE was not significantly effective on smaller polyps in small intestine (data not presented). IOAE (300 mg/kg) notably reduced the count of total polyps (35.5%) large polyps (52.2%) in large intestine but statistical significance was not achieved (P=0.081 and 0.061) (data not presented). A group of C57BL/6 mice, considered as negative control, treated only with vehiele control (water) showed no polyp development in the intestine (data not presented). This group was exeluded from further experimental procedures. These results confirm the in vivo antiproliferative effects of IOAE in the intestine of APC M inl +mice.
IOAE downregulates b-catenin signaling, induces apoptosis and suppresses inflammation pathway in APC M inl+ mice
Next, we investigated the effect ofIOAE on in situ expression ofcell proliferation mediators (Cyclin DI and c-Myc). IHC results showed increased staining of cyelin D I and c-Myc in intestinal epithelial cells of APCMinl+ mice that was suppressed by IOAE administration (Fig. 5Aa, Ab) . Overexpression of cyelin D I and c-Myc shows highly proliferating cellular milieu in the intestinal epithelium ofAPCMini . mice that was suppressed by IOAE. Immunoreactivity score (IRS) for quantitative analysis was recorded from the intensity and localization of antibody stains in the mucosal and submucosal layers of intestinal epithelium. IOAE suppressed the basal levels (3.2) ofCyelin D I to levels 1.4 and 1.5 at 100 and 300 mg! kg IOAE, respectively ( Fig. 5A graph a) . Similarly, the basal level (3.0) of c-Myc was suppressed to levels 1.2 and 1.8 at respective concentrations of lAOE ( Fig. 5A graph b) . These results demonstrate that IOAE interferes with the cellular proliferation signaling and suppresses the growth of polyps (Fig.  4) . To investigate the possible mechanism underlying this phenomenon, we analyzed the effect of IOAE on b-catenin signaling and its associated proteins in the small intestine of APC Minl + mice. As shown in Fig. 5B , IOAE inhibited the expression of b-catenin protein in a dose-dependent manner. IOAE inhibited the levels ofCDK-8 in similar fashion. IOAE caused apoptosis induction in the small intestine, as evident by reduced pro-caspase-3 and cleaved PARP (Fig.  5B ). Collectively, these results demonstrate that IOAE inhibited the development of polyps in the intestine of APCMinl + mice through downregulation of p-catenin signaling and induction of apoptosis. In order to investigate the anti-inflammatory function of IOAE in APCMinl + mice, we measured the in situ expression of inflammatory proteins (iNOS and Cox-2) by IHC staining. It is well known that iNOS, nitric oxide and Cox-2 are overproduced in the inflamed intestinal mucosa. Intestinal sections of APCMinl + mice showed high basal levels of iNOS and Cox-2 ( Fig. 5Ac, 4Ad) . The IRS recorded for iNOS was 3.6 that were significantly suppressed to 2 and 1.5 by IOAE at 100 and 300 mg/kg, respectively (Fig.  5A graph c) . Similarly, the IRS for Cox-2 (3.5) was significantly suppressed to 2.2 by IOAE ( Fig. 4 graph  d) . Suppression of these inflammatory mediators in intestinal tissues demonstrates the anti-inflammatory activity of IOAE that might be a key mechanism facilitating the inhibition of polyp growth in the intestine of APCMinJ+ mice.
IOAE suppresses tumor development and colonic inflammation in AOMlDSS-treated mice
To investigate the effect of IOAE on a chronic inflammatory condition and more aggressive tumor microenvironment, we used AOM-and DSS-induced carcinoma mice model. AOM is an indirect and genotoxic carcinogen requiring metabolic activation of CYP2El to exert its carcinogenic action. DSS is a non-genotoxic carcinogen in colon. AOM treatment followed by DSS exposure induces colonic neoplasms (18) . AOMIDSS-treated mice are novel mice models for CACC, histopathologically reminiscent of human chronic colitis and colitis-associated neoplasia (18) . C57BU6 mice were treated with a single dose ofAOM (10 mglkg) and then DSS (2%) in drinking water for 7 days. Colonic inflammation and mucosal injury in AOMIDSS-treated mice was analyzed by histological examination of H&E stained colon tissues (Fig. 6A ). Tissue sections from representative areas of colon of Fig. 4 graph  d) . Suppression of these inflammatory mediators in intestinal tissues demonstrates the anti-inflammatory activity of IOAE that might be a key mechanism facilitating the inhibition of polyp growth in the intestine of APCMinl+mice.
To investigate the effect of IOAE on a chronic inflammatory condition and more aggressive tumor microenvironment, we used AOM-and DSS-induced carcinoma mice model. AOM is an indirect and genotoxic carcinogen requiring metabolic activation of CYP2E I to exert its carcinogenic action. DSS is a non-genotoxic carcinogen in colon. AOM treatment followed by DSS exposure induces colonic neoplasms (18) . AOM/DSS-treated mice are novel mice models for CACC, histopathologically reminiscent of human chronic colitis and colitis-associated neoplasia (18) . C57BU6 mice were treated with a single dose ofAOM (10 mg/kg) and then DSS (2%) in drinking water for 7 days. Colonic inflammation and mucosal injury in AOMIDSS-treated mice was analyzed by histological examination of H&E stained colon tissues (Fig. 6A ). Tissue sections from representative areas of colon of . control mice showed intact surface epithelium, cryptal gland, stroma and submucosa. Colon sections from the AOMIDSS-treated mice showed distorted crypt epithelium, extensive mucosal damage and a large number of inflammatory cells in the microscopic analysis. IOAE treated sections showed relatively wellpreserved crypt structures and improved histological features (Fig. 6A) . IOAE administration showed a tendency to suppress tumor growth in the colon of AOMIDSS-treated mice (Fig. 6B ) with a significant drop (36.3%) in total tumor count at 300 mglkg concentration (P=O.017). Furthermore, we measured the size of tumors and classified them into two categories: small «2 mm) and large (>2mm). IOAE was found to be more effective on large tumors as compared to small tumors. Total count of large tumors was significantly reduced by IOAE treatment in a dosedependent manner (100 mglkg, P=O.112; 300 mglkg, P=O.OOI4) (Fig. 6B ). IOAE moderately suppressed small tumors also but statistically not significant (P>O.15). Then we analyzed the distribution of tumors in different regions of colon: proximal (first 1/3 length of colon from colocaecal junction), middle (second 1/3 length of colon after proximal), distal (third 1/3 length of colon adjacent to anal verge). The tendency of tumor development was increasing from proximal cytokines. In particular, the binding of TNF-a, IL-l~, and IL-6 to intestinal immune cells is suggested to exaggerate the immune response. Therefore, to gain further insight into the anti-inflammatory mechanisms in the suppressions of polyp development in APCMin!+ mice and tumor development in AOM/DSS-treated mice, we investigated the effects of IOAE on mRNA expression of inflammation related genes. The relative quantification of mRNA expressions of these genes was compared against samples with minimum band intensity (one-fold). In APCWin!+ mice, basal levels of pro-inflammatory cytokine genes IL-6, IL-I~, TNF-a, IFN-g, and iNOS were aberrantly high in the small intestine to 6.4-, 5.4-, 9-, 8.8-and 7-fold, respectively (Fig. 7A ). Administration of IOAE significantly reduced these increases to 2.1-1.7-fold at 100 and 300 mg!kg (Fig. 7A) . These results show strong antiinflammatory activity of IOAE in the small intestine of APCMin!+ mice. AOM/DSS-treated mice withstand hyper-activation ofimmune cells which drives them to inflammatory-related colon carcinogenesis. Colonic epithelium of these mice are known to produce high levels of pro-inflammatory cytokines, such as TNF-a, IFN-y, IL-l~and IL-6. We found that administration ofAOM and DSS caused aberrant expression of IL-6, IL-l~, TNF-a, IFN-g and iNOS in the colon of mice, as compared to non-AOM/DSS-treated mice (Fig.  7B ). The relative quantification ofmRNA expressions of these pro-inflammatory mediators was compared against non-AOM/DSS-treated mice. The relative mRNA level for IL-6, IL-l~, TNF-a, IFN-y, and iNOS genes were 6, 4.5, 7.3, 5 and 6.8, respectively (Fig. 7B ). Treatment with IOAE suppressed these increased levels in a dose-dependent manner to 3.8-1.2-fold at IOAE 100 and 300 mg/kg (Fig. 7B) .
These results show strong anti-inflammatory activity of IOAE in AOMJDSS-treated mice. Collectively, the results from APCMin!+ and AOM/DSS-treated mice demonstrate the anti-inflammatory potential of IOAE in the suppressions of polyp development and tumor growth in respective mice models. This antiinflammatory activity of IOAE may be attributed to the downregulation ofNF-KB signaling (Fig. 3A) , as observed in HCTll6 and DLD 1 cell lines.
DISCUSSION
towards distal (data not presented). The proximal region showed negligible tumor occurrence (l.0±0.02), the middle region had significant number of tumors (3.7±O.l8), and the distal region showed highest tumor count (7.9±0.16). IOAE dose-dependently reduced the tumor count in middle and distal regions of colon but statistically significant only for 300 mg/kg (middle, P=0.0082; distal P=0.036) (data not presented). These findings show that IOAE has site specific action in the colon of AOM/DSS-treated mice especially inhibiting large tumors in distal part of the colon. To observe the side effects of long term IOAE treatment, a group of mice was treated only with IOAE 300 mg/kg but no AOM/DSS. Mice in this group showed no known adverse physiological effects and histological signs in colon remain unaltered as compared to the vehicle control-treated mice (data not presented). This group was excluded from further experimental procedures.
One of the suggested mechanisms to explain the initiation of colonic injury-induced cancer is repetitive epithelial cell destruction and subsequent regeneration and high cellular proliferation. Thus, we assessed the proliferation and survival of intestinal epithelial cells in AOM/DSS-treated mice by IHC staining of cellular proliferation marker BrdU. Results showed aberrant increase in the proliferation ofcolon crypt cell in AOMJ DSS-treated mice as compared with non-AOM/DSS mice (vehicle control) ( Fig. 6C ). Treatment with IOAE at 300 mg/kg caused dramatic decrease in the BrdU positive staining of colonic epithelial cells in AOMJ DSS-treated mice (Fig. 6C ). Quantification of the IHC staining showed dramatic increase in BrdU positive staining ofcolonic epithelial cells in AOMJDSS-treated mice that was significantly decreased by IOAE 300 mg! kg (Fig. 60) . These results suggest that the proportion of actively proliferating cells was very high in the colon of AOMJDSS-treated mice that was suppressed by IOAE 300 mg/kg. Collectively, these results demonstrate that IOAE helps in maintaining colonic epithelial cell structures and improves histological damage in response to AOMJDSS and suppresses tumor growth in the colon. Cancer cells are characterized by diminished apoptosis and high cellular proliferation and thus reactivating apoptosis in cancer cells is a key approach to limit their uncontrolled proliferation (19) . In this study, we found that IOAE suppressed the proliferation ofHCTl16 and DDLl cells by inducing mitochondrial intrinsic pathway of apoptosis (Fig.  1) . IOAE induced S phase cell cycle arrest in DLD 1 cells (Fig. 1C) . Other studies have shown that boiling water extract of chaga causes cell cycle arrest at Gal G 1 in human hepatoma and melanola cell lines (20, 21) . Differences in the extraction procedure may lead to the variable chemical constituents in the extracts thereby varying effects on different cell lines. IOAE induced apoptosis also in APCMinl+ mice (Fig. 5B ). IOAE was also found to induce autophagic cell death in HCTl16 and DLD1 cells (Fig. 2B ). We also observed that IOAE suppressed the proliferation of breast cancer cell lines; MCF-7, MCF-10A, T47D, MDA-MB-231 and MDA-MB-468 (data not presented).
IOAE suppresses mRNA expression of proinflammatory mediators
The Wnt!~-catenin pathway occurs aberrantly activated in almost all CRCs under negative regulation by APC gene. Mutations in APC gene result in dysregulation of the Wnt signaling pathway leading to unregulated cell proliferation (4, 5) . In this study, IOAE suppressed the expression of b-catenin at cytoplasmic as well as nuclear levels (Fig. 3A) and led to the reduced transcriptional expression of c-Myc and cyclin D1 (Fig. 3B, 5 ). In addition, IOAE inhibited the levels of CDK-8 both in vitro and in vivo (Fig. 3B, 5B) . Reportedly, CDK-8 activity is necessary for b-catenin-driven transformation and suppression of CDK-8 inhibits the proliferation of colon cancer cells featuring b-catenin hyperactivity (22) . This suggests that therapeutic interventions targeting CDK-8 may be clinically beneficial in b-catenin-driven malignancies, and our results demonstrate that IOAE has such potential.
Therapeutic interventions against inflammationdriven carcinogenesis mainly include non-steroidal anti-inflammatory drugs which act by blocking prostanoid production from arachidonates through the inhibition ofCox-2 activity (3, 23) . Sensitization of cells with TNF-a is known to induce Cox-2 by one of its major positive transcriptional regulator NF-KB (3). In this study, IOAE suppressed the levels of Cox-2 ( Fig. 3B, 5A ), TNF-a (Fig. 7) , and iNOS ( Fig. 5A,  7) . iNOS acts as an important molecular crosslink with Cox-2 in tumorigenesis and is subsequently downregulated by Cox-2 inhibitors (24) . Therefore, Cox-2 plays important roles in various steps of carcinogenesis such as cell proliferation, reduction in apoptosis rates, and promotion oftumor angiogenesis (3, 23) . Therefore, inhibition of the Cox-2-iNOS crosslink by IOAE is highly considerable. These inflammatory mediators are transcriptionally regulated by NF-KB pathway which also up-regulates anti-apoptotic pathways (3). Among different subunits of NF-KB protein, phosphorylation of p65 subunit is required to stimulate Cox-2 expression (24) . IOAE caused reduction in the levels of p65 subunit in cytoplasmic as well as nuclear fractions (Fig. 3A) . The TCF4-~-catenin complex is known to crosstalk with NF-KB pathway, as a critical effector in colon carcinogenesis (25) . Fisetin (a plant flavonoid) showed apoptosis-inducing activity in colon cancer cells by inhibition of Cox-2 and Wnt! EGFRlNF-KB-signaling pathways (25) . We assume that IOAE-mediated suppression of nuclear levels of~-catenin might cause redundant TCF4-~-catenin binding. It further indicates that IOAE may inhibit the expression of Cox-2 apparently via TCF4-~ catenin and NF-KB at transcriptional level.
The hyper-activation of immune cells and overproduction of pro-inflammatory cytokines (IL-6, IL-1~, TNF-a and IFN-y) has been essentially associated with intestinal inflammation in IBD patients and also in animals (13) . Suppression ofIL-1~and IL-6 is been reported to inhibit the infiltration of inflammatory cells into the large intestine (26, 27) . Recently, we reported that IOAE suppressed the levels ofpro-inflammatory cytokines and ameliorates DSS-induced colitis in mice (13) . The present study demonstrates that IOAE suppressed the mRNA expression of pro-inflammatory cytokines (IL-6, ILl p, TNF-a and IFN-y) and iNOS in the small intestine ofAPC M il 1l+ (Fig. 7A ) and in the colon ofAOM/DSStreated mice (Fig. 7B) . Reduction in IL-l pand IL-6 levels by IOAE reflects a mechanistic approach associated with suppression of intestinal epithelial cell inflammation in mice. NF-KB pathway plays a central role in inflammation through transcriptional up-regulation of cytokines and chemokines like IL-IP and TNF-a (3), therefore, downregulation of NF-KB and concomitant inhibition of inflammation mediators appears to be a mechanism responsible for the anti-inflammatory effects ofIOAE.
Although the extract of lnonotus obliquus used in this study was not purified, we analyzed the chemical composition ofIOAE in our previous study (13) . We found that IOAE (per mg) contained: phenolics (57 ug), polysaccharides (204 ug) and proteins (127 ug) (13) . The biological activities oflnonotus obliquus are mainly attributed to the abundantly available molecules like polysaccharides, polyphenols, and peptides (9) . Other studies have reported comparatively similar values for these constituents of lnonotus obliquus with growth inhibitory and apoptosis-inducing activity in Sarcoma 180 cells (28) and antioxidant and antiproliferative activities in DLD 1 cells (29) . Although the total aqueous extract appears to be the limitation of this study, we assume that the effects of IOAE are largely ascribed to these compounds.
In conclusion, IOAE suppressed the proliferation of HCTll6 and DLDI cells and growths of intestinal tumors in APCMil1l+ and AOM/DSS-treated mice models. IOAE activated the mitochondrial intrinsic pathway of apoptosis, induced autophagy, and S phase cell cycle arrest. IOAE inhibited the expressions of iNOS and Cox-2 and proinflammatory cytokines, and ameliorated intestinal epithelial cell inflammation. IOAE downregulated the p-catenin and NF-KB signaling, which exerted anti-proliferative and anti-inflammatory activities in colorectal cancer cells. These properties of Inonotus obliquus advocate its use in as a supplement in colorectal cancer chemoprevention.
